Startups
Swissmedic is the national authorisation and supervisory authority for drugs and medical products. The agency ensures that only highquality, safe and effective medical products are available in Switzerland, thus making an important contribution to the protection of human and animal health.
Overview
Location
Switzerland, Bern
Employees
201-500
Mentions in press and media 20
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 11, 2025 | CUTISS Secures €57.9M, Propels Next-Gen Skin Regeneration | CUTISS secured €57.9M in Series C funding, propelling its advanced regenerative skin therapies forward. This significant capital boost supports denovoSkin, a bioengineered, personalized skin graft, through crucial Phase 3 clinical trials fo... |
| Sep 10, 2025 | CUTISS secures €57.9M Series C to advance regenerative skin therapies | Today CUTISS, a late-stage clinical TechBio at the forefront of tissue therapeutics and regenerative medicine, has announced the closing of its Series C round for €57.9 million (CHF 56M) with existing and new investors, bringing total funds... |
| May 6, 2025 | Private biotech companies set new records | During 2024, Switzerland’s biotech sector continued to demonstrate resilience despite significant financial and market challenges. Revenues remained strong at CHF 7.2 billion, while R&D investment grew to CHF 2.6 billion. Private biote... |
| Oct 17, 2024 | CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy | Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeuti... |
| Sep 20, 2024 | Regenera secures Orphan Drug Designation for its spinal cord injury therapy SpinoSave | Swiss-Austrian startup Regenera, incubated at USI Startup Centre and a member of the Austrian Cluster for Tissue Regeneration, has recently achieved a significant milestone by securing Orphan Drug Designation from both the European Medicin... |
| Nov 3, 2022 | Manufacturing roundup: Terumo Pharmaceutical Solutions expanding CDMO reach outside Japan; EUROAPI boosting production at Frankfurt site | The CDMO arm of the Terumo Corporation is looking to branch out of Japan and offer its services in other nations. Terumo Pharmaceutical Solutions will expand its CDMO services to customers on the global market. The co... |
| Jun 29, 2022 | Reimagining The Future of Pharmacovigilance (PV): Regulations, Tech, Public Perceptions | Barry Mulchrone, Senior Director& Head of Pharmacovigilance Oversight and Analytics, IQVIAAnnette Williams, VP & Global Head, Lifecycle Safety, IQVIA Monitoring the safe and effective use of medicines has now been an essential part ... |
| May 13, 2022 | Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation | Hansa Biopharma announces temporary marketing authorization in Switzerland for Idefirix[®] (imlifidase) in kidney transplantation Fri, May 13, 2022 08:00 CET Report this content Approval by Swissmedic1 enables highly sensitized patients in ... |
| Sep 27, 2021 | Takeda Pharmaceutical : Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn's Disease | - Alofisel (darvadstrocel) is the first expanded human allogeneic adipose-derived mesenchymal stem cell therapy to be approved in Japan - Alofisel provides a potential cell-mediated closure option for patients with complex perianal fistulas... |
Show more
Reviews 0
FAQ about Swissmedic
What has the press written about Swissmedic?
Parsers VC has collected 20 articles mentioning Swissmedic, among them “CUTISS Secures €57.9M, Propels Next-Gen Skin Regeneration” (Sep 11, 2025) and “CUTISS secures €57.9M Series C to advance regenerative skin therapies” (Sep 10, 2025).
Is Swissmedic still active?
Yes, Swissmedic is active; its latest activity on Parsers VC dates from Jan 15, 2026.